Format
Items per page
Sort by

Send to:

Choose Destination

Links from

Items: 1 to 20 of 118

1.

Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot study.

Su TI, Khanna D, Furst DE, Danovitch G, Burger C, Maranian P, Clements PJ.

Arthritis Rheum. 2009 Dec;60(12):3821-30. doi: 10.1002/art.24986.

2.

A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma.

Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S, Smith CD, Chalmers IM, Hong P, O'Hanlon D, Kaminska E, Markland J, Sibley J, Catoggio L, Furst DE.

Arthritis Rheum. 2001 Jun;44(6):1351-8.

3.
4.

Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center.

Pope J, McBain D, Petrlich L, Watson S, Vanderhoek L, de Leon F, Seney S, Summers K.

Arthritis Rheum. 2011 Nov;63(11):3547-51. doi: 10.1002/art.30549.

5.

Treatment of diffuse systemic sclerosis with hyperimmune caprine serum (AIMSPRO): a phase II double-blind placebo-controlled trial.

Quillinan NP, McIntosh D, Vernes J, Haq S, Denton CP.

Ann Rheum Dis. 2014 Jan;73(1):56-61. doi: 10.1136/annrheumdis-2013-203674. Epub 2013 Sep 25.

6.

Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192.

Denton CP, Merkel PA, Furst DE, Khanna D, Emery P, Hsu VM, Silliman N, Streisand J, Powell J, Akesson A, Coppock J, Hoogen Fv, Herrick A, Mayes MD, Veale D, Haas J, Ledbetter S, Korn JH, Black CM, Seibold JR; Cat-192 Study Group; Scleroderma Clinical Trials Consortium.

Arthritis Rheum. 2007 Jan;56(1):323-33.

7.

Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial.

Gordon JK, Martyanov V, Magro C, Wildman HF, Wood TA, Huang WT, Crow MK, Whitfield ML, Spiera RF.

Arthritis Res Ther. 2015 Aug 18;17:213. doi: 10.1186/s13075-015-0721-3.

8.

Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis.

Merkel PA, Silliman NP, Clements PJ, Denton CP, Furst DE, Mayes MD, Pope JE, Polisson RP, Streisand JB, Seibold JR; Scleroderma Clinical Trials Consortium.

Arthritis Rheum. 2012 Oct;64(10):3420-9. doi: 10.1002/art.34427.

9.

Effects of micronutrient antioxidants (alpha-tocopherol and ascorbic acid) on skin thickening and lung function in patients with early diffuse systemic sclerosis.

Ostojic P, Damjanov N.

Rheumatol Int. 2011 Aug;31(8):1051-4. doi: 10.1007/s00296-010-1398-1. Epub 2010 Mar 23.

PMID:
20309694
10.

A randomized, blinded, parallel group, placebo controlled pilot study evaluating the effect of PVAC treatment in patients with diffuse systemic sclerosis.

Genovese MC, Chakravarty EF, Boyle DL, Tutuncu Z, Thorburn CM, Halilhodzic M, Kroll S, Baughman J, Stewart S, Kavanaugh A.

J Rheumatol. 2005 Dec;32(12):2345-50.

PMID:
16331761
11.

Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial.

Prey S, Ezzedine K, Doussau A, Grandoulier AS, Barcat D, Chatelus E, Diot E, Durant C, Hachulla E, de Korwin-Krokowski JD, Kostrzewa E, Quemeneur T, Paul C, Schaeverbeke T, Seneschal J, Solanilla A, Sparsa A, Bouchet S, Lepreux S, Mahon FX, Chene G, Taïeb A.

Br J Dermatol. 2012 Nov;167(5):1138-44. doi: 10.1111/j.1365-2133.2012.11186.x. Epub 2012 Oct 5.

PMID:
23039171
12.

Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial.

Spiera RF, Gordon JK, Mersten JN, Magro CM, Mehta M, Wildman HF, Kloiber S, Kirou KA, Lyman S, Crow MK.

Ann Rheum Dis. 2011 Jun;70(6):1003-9. doi: 10.1136/ard.2010.143974. Epub 2011 Mar 11.

13.

B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis.

Lafyatis R, Kissin E, York M, Farina G, Viger K, Fritzler MJ, Merkel PA, Simms RW.

Arthritis Rheum. 2009 Feb;60(2):578-83. doi: 10.1002/art.24249.

14.

Observational study of treatment outcome in early diffuse cutaneous systemic sclerosis.

Herrick AL, Lunt M, Whidby N, Ennis H, Silman A, McHugh N, Denton CP.

J Rheumatol. 2010 Jan;37(1):116-24. doi: 10.3899/jrheum.090668. Epub 2009 Dec 1.

PMID:
19955050
15.

Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis.

Chakravarty EF, Martyanov V, Fiorentino D, Wood TA, Haddon DJ, Jarrell JA, Utz PJ, Genovese MC, Whitfield ML, Chung L.

Arthritis Res Ther. 2015 Jun 13;17:159. doi: 10.1186/s13075-015-0669-3.

16.

Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study.

Khanna D, Furst DE, Hays RD, Park GS, Wong WK, Seibold JR, Mayes MD, White B, Wigley FF, Weisman M, Barr W, Moreland L, Medsger TA Jr, Steen VD, Martin RW, Collier D, Weinstein A, Lally EV, Varga J, Weiner SR, Andrews B, Abeles M, Clements PJ.

Ann Rheum Dis. 2006 Oct;65(10):1325-9. Epub 2006 Mar 15.

17.

The correlation between durometer score and modified Rodnan skin score in systemic sclerosis.

Moon KW, Song R, Kim JH, Lee EY, Lee EB, Song YW.

Rheumatol Int. 2012 Aug;32(8):2465-70. doi: 10.1007/s00296-011-1993-9. Epub 2011 Jul 19.

PMID:
21769489
18.

An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis.

Denton CP, Engelhart M, Tvede N, Wilson H, Khan K, Shiwen X, Carreira PE, Diaz Gonzalez F, Black CM, van den Hoogen FH.

Ann Rheum Dis. 2009 Sep;68(9):1433-9. doi: 10.1136/ard.2008.096123. Epub 2008 Sep 9.

PMID:
18782794
19.

Efficacy and safety of methotrexate in articular and cutaneous manifestations of systemic lupus erythematosus.

Islam MN, Hossain M, Haq SA, Alam MN, Ten Klooster PM, Rasker JJ.

Int J Rheum Dis. 2012 Feb;15(1):62-8. doi: 10.1111/j.1756-185X.2011.01665.x. Epub 2011 Sep 21.

PMID:
22324948
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk